

Novosyn® CHD NOVOTILAC

STUDY

Novosyn® for Trocar Incision after Laparoscopic Appendectomy and Cholecystectomy



Care
Healing
Decision

NOVOTILAC

M Golling, V Breul, W Steurer, C Hoyuela, J F Julián, P Baumann




Description

To evaluate the incidence of complications in laparoscopic cholecystectomy and appendectomy using Novosyn® CHD versus Novosyn® to close trocar wound.

Design



International, multicentric, randomized, double-blinded prospective



Objective

Novosyn® CHD will decrease the surgical site infection (SSI: A1 and A2) rate in comparison to **Novosyn®** until 30 days postoperatively.

Centers



4 centers:
2 Germany and 2 Spain

Patients



323 patients:
161 Novosyn® CHD and
162 Novosyn®

► The Results



- Lower SSI rate observed with Novosyn® CHD compared to Novosyn®*.
- Novosyn® CHD is **safe and well-eligible to close trocar incisions** after different surgical interventions.
- Novosyn® CHD can be considered an **alternative to Triclosan-coated sutures** currently in clinical use.
- **Excellent surgical handling** and **cosmetic result**.
- **Improved postoperative quality of life** in both treatment groups.

6.2 %
SSI Novosyn®

3.8 %
SSI Novosyn® CHD



*p=0.44



Access to
NOVOTILAC study



<https://pmc.ncbi.nlm.nih.gov/articles/PMC12165995/>



B. Braun Surgical, S.A. | Carretera de Terrassa, 121 | 08191 Rubí | Spain
Phone +34 93 586 6200 | www.bbraun.com

AESCULAP® – a B. Braun brand

Aesculap AG | Am Aesculap-Platz | 78532 Tuttlingen | Germany
Phone +49 7461 95-0 | www.aesculap.com

The main product trademark "Aesculap" and the product trademark "Novosyn" are registered trademarks of Aesculap AG.

Subject to technical changes. All rights reserved. This brochure may only be used for the exclusive purpose of obtaining information about our products. Reproduction in any form partial or otherwise is not permitted.

B65102 0725/x/2